Contralateral prophylactic mastectomy for patients with unilateral breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 8, 2007, Pages 1117-1122

  Tuttle, Todd ^a   Habermann, Elizabeth ^b   Abraham, Anasooya ^a   Emory, Tim ^a   Virnig, Beth ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Breast magnetic resonance imaging; Contralateral prophylactic mastectomy; Prevention; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYTOTOXIC AGENT; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PATIENT SATISFACTION; REVIEW; RISK REDUCTION; SECOND CANCER; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; TREATMENT INDICATION;

BREAST NEOPLASMS; DECISION MAKING; HUMANS; MASTECTOMY; PATIENT SATISFACTION; RISK;

EID: 34548444028     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.8.1117     Document Type: Review

References (46)

1. Robbins GF, Berg JW. Bilateral primary breast cancer: a prospective dinicopathological study. Cancer 17, 1501-1527 (1964).
2. Storm H H, Jensen OM. Risk of contralateral breast cancer in Denmark 1943-1980. Br. J. Cancer 54(3), 483-492 (1986).
3. Prior P, Waterhouse JA. The incidence of bilateral breast cancer. II: a proposed model for the analysis of coincidental tumours. Br. J. Cancer 43(5), 615-622 (1981).
4. Adami H O, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 55(3), 643-647 (1985).
5. Peralta EA, Ellenhorn D, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am. J. Surg. 180(6), 439-445 (2000).
6. McDonnell SK, Schaid DJ, Myers JL et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J. Clin. Oncol. 19(19), 3938-3943 (2001).
7. Herrinton LJ, Barlow WE, Yu O et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J. Clin. Oncol. 23(19), 4275-4286 (2005).
8. van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction of a contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers Br. J. Cancer 93(3), 287-292 (2005).
9. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am. Surg 59(11), 733-735 (1993).
10. Nielsen M, Christensen L, Andersen J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma Cancer 57(5), 897-903 (1986).
11. Wanebo H J, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J. Bilateral breast cancer. Risk reduction by contralateral biopsy. Ann. Surg 201(6), 667-677 (1985).
12. Goldflam K, Hunt KK, Gershenwald JE et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings Cancer 101(9), 1977-1986 (2004).
13. Slanetz PJ, Edmister WB, Yeh ED, Talele AC, Kopans DB. Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J. 8(3), 145-148 (2002).
14. Lehman CD, Gatsonis C, Kuhl CK et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N. Engl. J. Med. 356, 1295-303 (2007).
15. Liberman L. Breast MR imaging in assessing extent of disease. Magn. Reson. Imaging Clin. N. Am. 14(3), 339-349, vi (2006).
16. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int. J. Radiat. Oncol. Biol. Phys 56(4), 1038-1045 (2003).
17. Fung MC, Schultz DJ, Solin LJ. Early-stage bilateral breast cancer treated with breast-conserving surgery and definitive irradiation: the University of Pennsylvania experience. Int. J. Radiat. Oncol. Biol. Phys 38(5), 959-967 (1997).
18. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
19. Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival and tumour characteristics of breast-cancer petients with germline mutations of BRCA1. Lancet 351 (9099), 316-321 (1998).
20. Erdreich LS, Asal NR, Hoge AF. Morphologic types of breest cancer: age, bilaterality, and family history. South Med. J 73(1), 28-32 (1980).
21. Yeetman T J, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann. Surg Oncol. 4(3), 198-202 (1997).
22. Sacchini V, Pinotti JA, Barros AC et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J. Am. Coll. Surg. 203(5), 704-714 (2006).
23. Simmons RM, Brennan M, Christos P, King V, Osborne M. Analysis of nipple/ areolar involvement with mastectomy: can the areola be preserved? Ann. Srug Oncol. 9(2), 165-168 (2002).
24. Boughey JC, Khakpour N, Merio-Bernstam F et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7), 1440-1447 (2006).
25. King TA, Ganaraj A, Fey JV et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events experience in patients under going prophylactic mastectomy. Cancer 101(5), 926-933 (2004).
26. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst. Rev. (4), CD002748 (2004).
27. Schrag D, Kuntz KM, Garger JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283, 617-214 (2000).
28. Barton MB, West CN, Liu IL et al. Complications following bilateral prophylactic mastectomy. J. Natl Cancer Inst. Monogr. 35, 61-66 (2005).
29. Frost MH, Slezak JM, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J. Clin. Oncol. 23(31), 7849-7856 (2005).
30. Montgomery LL, Tran KN, Heelan MC et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann. Surg Oncol. 6(6), 546-552 (1999).
31. Geiger AM, West CN, Nekhlyudov L. et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J. Clin. Oncol. 24(9), 1350-1356 (2006).
32. Tercyak KP, Peshkin BN, Brogan BM et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J. Clin. Oncol. 25, 285-291 (2007).
33. Tuttle T, Habermann E, Grund E, Morris T, Virnig B. Increasing used contralateral prophylactic mastectomy for breast cancer patients a trend toward more aggressive surgical treatment. Presented at: Annual Meeting Society Surgical Oncology. Washington, DC, USA, 16 March 2007 (Abstract 19).
34. Polednak AP. Frequency of prophylactic oontralateral mastectomy among breast cancer patients. J. Am. Coll. Surg 192(6), 804-805 (2001).
35. Nekhlyudov L, Bower M, Herrinton LJ et al. Women's decision-making roles regarding contralateral prophylactic mastectomy. J. Natl Cancer Inst. Monogr. 35, 55-60 (2005).
36. Schwartz MD, Lerman C, Brogan B et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J. Clin. Oncol. 22(10), 1823-1829 (2004).
37. Ciatto S, Ambrogatti D, Bonardi R, Bravetti P, Del Turco MR. Prognostic impact of early detection of contralateral primary breast cancer. Tumori 76(4), 370-373 (1990).
38. Mellink WA, Holland R, Hendriks JH, Peeters PH, Rutgers EJ, van Daal WA. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 67(7), 1844-1848 (1991).
39. Burns PE, Dabbs K, May C et al. Bilateral breast cancer in northern Alberta risk factors and survival patterns. Can. Med. Assoc. J. 130(7), 881-886 (1984).
40. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl Cancer. Inst. 83(18), 1278-1280 (1991).
41. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J. Natl. Cancer Inst. Monogr. 11, 117-120 (1992).
42. Rutqvist LE, Cedermark B, Glass U et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvent tamoxifen therapy. J. Natl. Cancer Inst. 83(18), 1299-1306 (1991).
43. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers' a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356(9245), 1876-1881 (2000).
44. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versustamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002).
45. Meekin JW, Hayward JL, Panzarella T et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat. 37(1), 11-19 (1996).
46. Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group. Lancet 351(9114), 1451-1467 (1998).